NCT01456182View on ClinicalTrials.gov

Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

May 31, 2013

Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
DRUG

AFX-2

Dose level 1

DRUG

AFX-2

Dose level 2

DRUG

AFX-2

Dose level 3

DRUG

AFX-2

Dose level 4

DRUG

AFX-2

Dose level 5

Trial Locations (3)

27157

Comprehensive Cancer Center of Wake Forest University, Winston-Salem

29615

Cancer Center of the Carolinas, Greenville

48106

Saint Jospeh Mercy Health System, Ann Arbor

Sponsors
All Listed Sponsors
lead

Afexa Life Sciences Inc

INDUSTRY